Pioneering Sustained
NITRIC OXIDE
Delivery Systems
Harnessing the power of NO for anti-microbial, anti-inflammatory, and anti-thrombotic therapies.
Contact Us
A New Paradigm in
Biopharmaceutical
Innovation
Nytricx is revolutionizing infection prevention and vascular health by mimicking the body’s natural release of nitric oxide (NO). A game-changing antimicrobial solutions for catheters and wound care — addressing a $30B+ global market
The Problem We Solve
Infections from medical devices are a silent global crisis.
- Wound Infections: Millions face non-healing wounds, amputations, and severe complications.
- Catheter-Associated Infections: 1.7M US hospital infections annually, $10B in costs.
- Current Solutions Fail: Antibiotic resistance is growing, and silver coatings are not enough.
Our Breakthrough Solution
Nytricx products safely release controlled levels of NO — the body’s natural antimicrobial and anti-clotting molecule — directly where it’s needed, preventing infection and saving lives.
Wound Dressing (With or Without TXA)
Nytricx’s advanced wound patch releases nitric oxide (NO)—the body’s natural defense molecule—continuously over 3 to 12 days, helping to kill harmful bacteria, reduce inflammation, and promote healing. Thin, flexible, and easy to apply, it offers a breakthrough solution for chronic and traumatic wounds, without antibiotics or risk of resistance.
Catheter Inserts
Nytricx’s catheter inserts release nitric oxide (NO) inside any standard catheter, preventing dangerous infections and blood clots. The insert’s fiber-optic technology allows real-time control of NO release using a smartphone, offering a smarter, safer way to protect patients without antibiotics.
A Multi-Billion Global Market
We’re Ready to Lead
- $30B projected market by 2028 (wounds + catheters).
- 50–60% of diabetic wounds get infected.
- 1.7M US hospital-acquired infections annually.
- NO-releasing technology: no resistance, no systemic antibiotics.
Nytricx: A University of Georgia Spinout with $6.2M Non-Dilutive Funding
Nytricx, Inc. nitric oxide research has roots in the development and testing facilities at the University of Georgia, College of Engineering Research Laboratories of Dr. Hitesh Handa and Elizabeth Brisbois
- Innovators in NO-based medical devices
- Proven preclinical results: 99.9% MRSA kill rate in 3 days
- Strong IP: 6 patents issued, 20+ pending
- Scientific leadership from UGA’s top labs
Seeking $10M Series A for Clinical Development
- $2M Finalize Formulation & Safety Testing
- $4M Manufacturing & Regulatory
- $4M Phase II Clinical Studies
Contact Us
Ronald Shebuski,
PhD, President and CEO
